Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

EHA 2019 /
CD33 T cell recruiting antibody constructs for treatment of relapsed refractory AML

13th - 16th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 19.06.19
Views: 916
Rating:

Prof Marion Subklewe - LMU Hospital Munich, Munich, Germany

Prof Marion Subklewe speaks to ecancer at the 2019 European Hematology Association (EHA) Annual Meeting about CD33 T cell recruiting antibody constructs for treatment of relapsed refractory AML.

She reports that while they are recruiting patients for ongoing phase I trials, they hope to identify parameters that influence BiTE mediated toxicity and effectivity.

Prof Subklewe discusses the findings from three posters on this topic presented at the meeting and their implications on future research in this area.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation